The clinical value of optical-assisted lateral flow assay to monitor the anti-SARS-CoV-2 neutralizing antibody after receiving novel coronavirus pneumonia (COVID-19) vaccine

The clinical value of optical-assisted lateral flow assay to monitor the anti-SARS-CoV-2 neutralizing antibody after receiving SARS-CoV-2 vaccine

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045417

Enrollment

Unknown

Registered

2021-04-14

Start date

2021-04-19

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Gold Standard:Anti-SARS-CoV-2 neutralizing antibody ELISA kit

Index test:Anti-SARS-CoV-2&#32

optical-assisted&#32

flow&#32

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged greater than 18 years without sex restriction, and written informed consent has been provided; 2.There are no contraindications to vaccination for healthy people who have perfected the new crown vaccination in the Fifth Affiliated Hospital of Sun Yat-Sen University.

Exclusion criteria

Exclusion criteria: 1. Long-term use of steroid and immunosuppressant; 2. Patients suffering from autoimmune diseases.

Design outcomes

Primary

Measure	Time frame
Vaccine immunoreactivity;	—

Countries

China

Contacts

Public ContactXiao Fei

the Fifth Affiliated Hospital of Sun Yat-Sen University

xiaof35@mail.sysu.edu.cn+86 13380600018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026